Vyxeos® With Clofarabine for Pediatric AML

NCT07156435 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Pediatric AML
Refractory Pediatric AML

Interventions

DRUG: Vyxeos 44 MG / 100 MG Liposome Injection
DRUG: Clofarabine

Sponsor

Princess Maxima Center for Pediatric Oncology

Collaborators

[object Object]